Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 145 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: metoprolol tartrate Clear all
Completed Not applicable Interventional

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

NCT03943927
View directory record Official record
Conditions
Post-operative Atrial Fibrillation
Interventions
Guided Metoprolol Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 25, 2026, 1:13 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 25, 2026, 1:13 PM EDT
Withdrawn Not applicable Interventional

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

NCT01330654
View directory record Official record
Conditions
Cardiac Event Risk
Interventions
metoprolol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses 2

NCT01203852
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Chlorthalidone
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 25, 2026, 1:13 PM EDT
Terminated Phase 4 Interventional Results available

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 25, 2026, 1:13 PM EDT
Terminated Phase 4 Interventional

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

NCT02025465
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

NCT01914926
View directory record Official record
Conditions
Heart Rate and Rhythm Disorders
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

NCT00060931
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
119
States / cities
Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 25, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
View directory record Official record
Conditions
Heart Diseases
Interventions
Metoprolol Tartrate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 25, 2026, 1:13 PM EDT
Terminated Phase 2Phase 3 Interventional

Protective Effects of Propranolol in Adults

NCT01902810
View directory record Official record
Conditions
Burn
Interventions
Propranolol, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Gainesville, Florida • Maywood, Illinois • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 25, 2026, 1:13 PM EDT
Withdrawn Phase 2 Interventional

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

NCT05147415
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Placebo, Tesomet
Other · Drug
Lead sponsor
Saniona
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 25, 2026, 1:13 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

NCT00123604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Carvedilol, Metoprolol
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of BMS-914392 on Pharmacokinetics of Metoprolol

NCT01211821
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
metoprolol, BMS-914392
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

NCT02940379
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
sotagliflozin (SAR439954), midazolam, metoprolol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

NCT00953212
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
beta blockers, amiodarone, ascorbic acid
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Pilot - Peri-operative Beta Blockade

NCT02746575
View directory record Official record
Conditions
Adrenergic Beta-Receptor Blockader, Troponin Levels, Cardiomyopathy, Post-surgical
Interventions
metoprolol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
51 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

CAndesartan vs LIsinopril Effects on the BRain

NCT01984164
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Candesartan, Lisinopril
Drug
Lead sponsor
Emory University
Other
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 25, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009
View directory record Official record
Conditions
High Blood Pressure
Interventions
Nebivolol, Metoprolol XL
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 25, 2026, 1:13 PM EDT